Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major obstructive sleep apnea markets reached a value of US$ 424.2 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 639.4 Million by 2034, exhibiting a growth rate (CAGR) of 3.8% during 2024-2034.
The obstructive sleep apnea market has been comprehensively analyzed in IMARC's new report titled "Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obstructive sleep apnea refers to a sleep disorder characterized by repetitive interruptions in breathing during sleep. These interruptions, known as apneas, occur when the muscles in the throat fail to keep the airway open, resulting in partial or complete blockage of airflow. The obstruction can lead to a decrease in oxygen levels in the body, causing the patient to briefly wake up or experience shallow sleep in order to restore normal breathing. The most common symptoms associated with the ailment include loud snoring, excessive daytime sleepiness, gasping or choking during sleep, morning headaches, difficulty concentrating, irritability, restless sleep, etc. The diagnosis of the condition typically involves a thorough evaluation by a healthcare professional specializing in sleep disorders. It begins with a detailed assessment of the patient's medical history, symptoms, and risk factors. The healthcare provider may use questionnaires, such as the Epworth Sleepiness Scale, to assess daytime sleepiness. In many cases, a sleep study, either in a sleep laboratory or through a home-based sleep test, is conducted to confirm the diagnosis.
The rising cases of chronic nasal congestion due to allergies, sinus problems, nasal polyps, etc., which lead to partial or complete blockage of airflow, are primarily driving the obstructive sleep apnea market. Furthermore, the increasing prevalence of several associated risk factors, such as enlarged tonsils or adenoids, obesity, genetic predisposition, use of sedatives, smoking, etc., is also propelling the market growth. Besides this, the widespread adoption of uvulopalatopharyngoplasty for treating the ailment on account of its numerous benefits, including reduced apnea-hypopnea index, improved airflow, decreased cardiovascular risk, etc., is acting as another significant growth-inducing factor. Additionally, the inflating usage of mandibular advancement devices that are custom-made to fit the patient's mouth and work by repositioning the jaw to help keep the airway open during sleep is further bolstering the market growth. Apart from this, the escalating demand for hypoglossal nerve stimulation (HNS), which involves implanting a device to stimulate the hypoglossal nerve that controls tongue movement and other muscles involved in maintaining airway patency for improved breathing during sleep, is expected to drive the obstructive sleep apnea market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the obstructive sleep apnea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obstructive sleep apnea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obstructive sleep apnea market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the obstructive sleep apnea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the obstructive sleep apnea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current obstructive sleep apnea marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the obstructive sleep apnea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the obstructive sleep apnea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the obstructive sleep apnea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea across the seven major markets?
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with obstructive sleep apnea across the seven major markets?
What is the size of the obstructive sleep apnea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of obstructive sleep apnea?
What will be the growth rate of patients across the seven major markets?
Obstructive Sleep Apnea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for obstructive sleep apnea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obstructive sleep apnea market?
What are the key regulatory events related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by status related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by phase related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by route of administration related to the obstructive sleep apnea market?
The obstructive sleep apnea market has been comprehensively analyzed in IMARC's new report titled "Obstructive Sleep Apnea Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Obstructive sleep apnea refers to a sleep disorder characterized by repetitive interruptions in breathing during sleep. These interruptions, known as apneas, occur when the muscles in the throat fail to keep the airway open, resulting in partial or complete blockage of airflow. The obstruction can lead to a decrease in oxygen levels in the body, causing the patient to briefly wake up or experience shallow sleep in order to restore normal breathing. The most common symptoms associated with the ailment include loud snoring, excessive daytime sleepiness, gasping or choking during sleep, morning headaches, difficulty concentrating, irritability, restless sleep, etc. The diagnosis of the condition typically involves a thorough evaluation by a healthcare professional specializing in sleep disorders. It begins with a detailed assessment of the patient's medical history, symptoms, and risk factors. The healthcare provider may use questionnaires, such as the Epworth Sleepiness Scale, to assess daytime sleepiness. In many cases, a sleep study, either in a sleep laboratory or through a home-based sleep test, is conducted to confirm the diagnosis.
The rising cases of chronic nasal congestion due to allergies, sinus problems, nasal polyps, etc., which lead to partial or complete blockage of airflow, are primarily driving the obstructive sleep apnea market. Furthermore, the increasing prevalence of several associated risk factors, such as enlarged tonsils or adenoids, obesity, genetic predisposition, use of sedatives, smoking, etc., is also propelling the market growth. Besides this, the widespread adoption of uvulopalatopharyngoplasty for treating the ailment on account of its numerous benefits, including reduced apnea-hypopnea index, improved airflow, decreased cardiovascular risk, etc., is acting as another significant growth-inducing factor. Additionally, the inflating usage of mandibular advancement devices that are custom-made to fit the patient's mouth and work by repositioning the jaw to help keep the airway open during sleep is further bolstering the market growth. Apart from this, the escalating demand for hypoglossal nerve stimulation (HNS), which involves implanting a device to stimulate the hypoglossal nerve that controls tongue movement and other muscles involved in maintaining airway patency for improved breathing during sleep, is expected to drive the obstructive sleep apnea market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the obstructive sleep apnea market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for obstructive sleep apnea and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the obstructive sleep apnea market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the obstructive sleep apnea market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the obstructive sleep apnea market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current obstructive sleep apnea marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the obstructive sleep apnea market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the obstructive sleep apnea market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the obstructive sleep apnea market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea across the seven major markets?
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of obstructive sleep apnea by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with obstructive sleep apnea across the seven major markets?
What is the size of the obstructive sleep apnea patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of obstructive sleep apnea?
What will be the growth rate of patients across the seven major markets?
Obstructive Sleep Apnea: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for obstructive sleep apnea drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the obstructive sleep apnea market?
What are the key regulatory events related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by status related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by phase related to the obstructive sleep apnea market?
What is the structure of clinical trial landscape by route of administration related to the obstructive sleep apnea market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OBSTRUCTIVE SLEEP APNEA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OBSTRUCTIVE SLEEP APNEA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OBSTRUCTIVE SLEEP APNEA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OBSTRUCTIVE SLEEP APNEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OBSTRUCTIVE SLEEP APNEA - UNMET NEEDS
10 OBSTRUCTIVE SLEEP APNEA - KEY ENDPOINTS OF TREATMENT
11 OBSTRUCTIVE SLEEP APNEA - MARKETED PRODUCTS
11.1 List of Obstructive Sleep Apnea Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 OBSTRUCTIVE SLEEP APNEA - PIPELINE DRUGS
12.1 List of Obstructive Sleep Apnea Pipeline Drugs Across the Top 7 Markets
12.1.1 Lemborexant - Eisai
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AD109 - Apnimed
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TAK-925 - Takeda
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 IHL42X - Incannex Healthcare
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OBSTRUCTIVE SLEEP APNEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OBSTRUCTIVE SLEEP APNEA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OBSTRUCTIVE SLEEP APNEA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Obstructive Sleep Apnea - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Obstructive Sleep Apnea - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Obstructive Sleep Apnea - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Obstructive Sleep Apnea - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Obstructive Sleep Apnea - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Obstructive Sleep Apnea - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Obstructive Sleep Apnea - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Obstructive Sleep Apnea - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Obstructive Sleep Apnea - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Obstructive Sleep Apnea - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Obstructive Sleep Apnea - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Obstructive Sleep Apnea - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Obstructive Sleep Apnea - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Obstructive Sleep Apnea - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Obstructive Sleep Apnea - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Obstructive Sleep Apnea - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
16 OBSTRUCTIVE SLEEP APNEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OBSTRUCTIVE SLEEP APNEA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OBSTRUCTIVE SLEEP APNEA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OBSTRUCTIVE SLEEP APNEA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OBSTRUCTIVE SLEEP APNEA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OBSTRUCTIVE SLEEP APNEA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OBSTRUCTIVE SLEEP APNEA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OBSTRUCTIVE SLEEP APNEA - UNMET NEEDS
10 OBSTRUCTIVE SLEEP APNEA - KEY ENDPOINTS OF TREATMENT
11 OBSTRUCTIVE SLEEP APNEA - MARKETED PRODUCTS
11.1 List of Obstructive Sleep Apnea Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 OBSTRUCTIVE SLEEP APNEA - PIPELINE DRUGS
12.1 List of Obstructive Sleep Apnea Pipeline Drugs Across the Top 7 Markets
12.1.1 Lemborexant - Eisai
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AD109 - Apnimed
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 TAK-925 - Takeda
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 IHL42X - Incannex Healthcare
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OBSTRUCTIVE SLEEP APNEA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OBSTRUCTIVE SLEEP APNEA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OBSTRUCTIVE SLEEP APNEA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Obstructive Sleep Apnea - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Obstructive Sleep Apnea - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Obstructive Sleep Apnea - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Obstructive Sleep Apnea - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Obstructive Sleep Apnea - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Obstructive Sleep Apnea - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Obstructive Sleep Apnea - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Obstructive Sleep Apnea - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Obstructive Sleep Apnea - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Obstructive Sleep Apnea - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Obstructive Sleep Apnea - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Obstructive Sleep Apnea - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Obstructive Sleep Apnea - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Obstructive Sleep Apnea - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Obstructive Sleep Apnea - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Obstructive Sleep Apnea - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Obstructive Sleep Apnea - Access and Reimbursement Overview
16 OBSTRUCTIVE SLEEP APNEA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OBSTRUCTIVE SLEEP APNEA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OBSTRUCTIVE SLEEP APNEA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
